Literature DB >> 16140275

Double blockade of cell cycle progression by coptisine in vascular smooth muscle cells.

H Tanabe1, H Suzuki, H Mizukami, M Inoue.   

Abstract

Coptisine, an isoquinoline alkaloid isolated from rhizome of Coptis japonica, inhibits proliferation of vascular smooth muscle cells (VSMCs). The aim of this study was to evaluate the action of coptisine, along with berberine (a structurally similar isoquinoline alkaloid), on progression of the cell cycle in VSMCs. Coptisine displayed antiproliferative action against VSMCs by blocking the cell cycle at G(1) and G(2)/M phases. The G(1) block was shown by inhibition of [(3)H]thymidine incorporation into VSMCs at coptisine concentrations higher than 15 microM. The mechanism underlying the G(1) arrest involved a decrease in cyclin D1 protein, although cyclin E, A, and B were not affected by coptisine treatment. The selective reduction in cyclin D1 protein was mainly attributable to accelerated proteolysis via proteasome-dependent pathway, since it was inhibited by a proteasome inhibitor, N-carbobenzoxy-L-leucinyl-L-leucinyl-L-norleucinal (MG132) and further the mRNA level of cyclin D1, protein synthesis, and mitogen-activated protein kinase (MAPK) activity remained unaltered. The mechanism underlying the G(2)/M arrest involved partial inhibition of tubulin polymerization, which was apparent at coptisine concentration of 3 microM. Berberine arrested the cell cycle at G(1) phase via a mechanism identical with coptisine, but did not cause block at G(2)/M phase. The results demonstrate that a small difference in the structure between isoquinoline alkaloids produces a big difference in activity, and that coptisine has a unique double action in arresting the cell cycle of VSMCs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16140275     DOI: 10.1016/j.bcp.2005.07.010

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Application of 1H-NMR spectroscopy to validation of berberine alkaloid reagents and to chemical evaluation of Coptidis Rhizoma.

Authors:  Keiko Hasada; Takamitsu Yoshida; Takeshi Yamazaki; Naoki Sugimoto; Tetsuji Nishimura; Akito Nagatsu; Hajime Mizukami
Journal:  J Nat Med       Date:  2010-12-25       Impact factor: 2.343

Review 2.  Advance of studies on anti-atherosclerosis mechanism of berberine.

Authors:  Min Wu; Jie Wang; Long-tao Liu
Journal:  Chin J Integr Med       Date:  2010-05-16       Impact factor: 1.978

3.  Identification of a new pharmacological activity of the phenylpiperazine derivative naftopidil: tubulin-binding drug.

Authors:  Kenichiro Ishii; Yoshiki Sugimura
Journal:  J Chem Biol       Date:  2014-09-06

4.  Coptisine from Rhizoma Coptidis Suppresses HCT-116 Cells-related Tumor Growth in vitro and in vivo.

Authors:  Tao Huang; Yubo Xiao; Lin Yi; Ling Li; Meimei Wang; Cheng Tian; Hang Ma; Kai He; Yue Wang; Bing Han; Xiaoli Ye; Xuegang Li
Journal:  Sci Rep       Date:  2017-02-06       Impact factor: 4.379

Review 5.  Berberis vulgaris for cardiovascular disorders: a scoping literature review.

Authors:  Abdelrahman Ibrahim Abushouk; Amr Muhammad Abdo Salem; Mohamed M Abdel-Daim
Journal:  Iran J Basic Med Sci       Date:  2017-05       Impact factor: 2.699

Review 6.  Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics.

Authors:  Xiaojun Feng; Antoni Sureda; Samineh Jafari; Zahra Memariani; Devesh Tewari; Giuseppe Annunziata; Luigi Barrea; Sherif T S Hassan; Karel Šmejkal; Milan Malaník; Alice Sychrová; Davide Barreca; Lovro Ziberna; Mohamad Fawzi Mahomoodally; Gokhan Zengin; Suowen Xu; Seyed Mohammad Nabavi; Ai-Zong Shen
Journal:  Theranostics       Date:  2019-03-16       Impact factor: 11.556

7.  Disruption of nucleocytoplasmic trafficking of cyclin D1 and topoisomerase II by sanguinarine.

Authors:  Jon Holy; Genelle Lamont; Edward Perkins
Journal:  BMC Cell Biol       Date:  2006-03-02       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.